Recombinant Antibodies for Autoimmune Diagnostics.

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

9963.1;5 PFLS-LS

Projekttitel

Recombinant Antibodies for Autoimmune Diagnostics.

Projekttitel Englisch

Recombinant Antibodies for Autoimmune Diagnostics

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung	-	-	-
Abstract	-	-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Englisch)	Recombinant Antibodies for Autoimmune Diagnostics.
Abstract (Englisch)	(Feasibility Study, 7-months). This project will pursue the development of advanced assays for human autoimmune diagnosis or disease-state monitoring. In particular, measuring autoimmune response requires having the appropriate human antibodies as necessary for assay development, reference and standardization. As a first step, we will develop recombinant human-mouse chimeric antibodies, specifically anti-ganglioside and anti-myelin-associated glycoprotein (MAG). These will serve functionally as humansimilar material for assay applications, where otherwise human material from natural sources e.g. isolated from diseased individuals, has long proven to be restricting. In the future, we envision a full-spectrum platform, from antigen design or synthesis to the isolation of binding-specific antibodies, followed by recombinant protein expression through full development of further unique diagnostic assays.

Kategorie

Text

Kurzbeschreibung
(Englisch)

Recombinant Antibodies for Autoimmune Diagnostics.

Abstract
(Englisch)

(Feasibility Study, 7-months). This project will pursue the development of advanced assays for human autoimmune diagnosis or disease-state monitoring. In particular, measuring autoimmune response requires having the appropriate human antibodies as necessary for assay development, reference and standardization. As a first step, we will develop recombinant human-mouse chimeric antibodies, specifically anti-ganglioside and anti-myelin-associated glycoprotein (MAG). These will serve functionally as humansimilar material for assay applications, where otherwise human material from natural sources e.g. isolated from diseased individuals, has long proven to be restricting. In the future, we envision a full-spectrum platform, from antigen design or synthesis to the isolation of binding-specific antibodies, followed by recombinant protein expression through full development of further unique diagnostic assays.